287 related articles for article (PubMed ID: 21331764)
1. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Blechacz BR; Smoot RL; Bronk SF; Werneburg NW; Sirica AE; Gores GJ
Hepatology; 2009 Dec; 50(6):1861-70. PubMed ID: 19821497
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
[TBL] [Abstract][Full Text] [Related]
4. [Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
Huang FK; Shi Z
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):808-12. PubMed ID: 21223684
[TBL] [Abstract][Full Text] [Related]
5. Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
LaRocca RV; Hicks MD; Mull L; Foreman B
J Gastrointest Cancer; 2007; 38(2-4):154-6. PubMed ID: 19089671
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
Kim DH; Jeong YI; Chung CW; Kim CH; Kwak TW; Lee HM; Kang DH
Int J Nanomedicine; 2013; 8():1697-711. PubMed ID: 23658488
[TBL] [Abstract][Full Text] [Related]
7. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
[TBL] [Abstract][Full Text] [Related]
8. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
[TBL] [Abstract][Full Text] [Related]
12. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Hu S; Niu H; Inaba H; Orwick S; Rose C; Panetta JC; Yang S; Pounds S; Fan Y; Calabrese C; Rehg JE; Campana D; Rubnitz JE; Baker SD
J Natl Cancer Inst; 2011 Jun; 103(11):893-905. PubMed ID: 21487100
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib exerts anti-glioma activity in vitro and in vivo.
Siegelin MD; Raskett CM; Gilbert CA; Ross AH; Altieri DC
Neurosci Lett; 2010 Jul; 478(3):165-70. PubMed ID: 20470863
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
15. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Huynh H; Ngo VC; Koong HN; Poon D; Choo SP; Thng CH; Chow P; Ong HS; Chung A; Soo KC
J Cell Mol Med; 2009 Aug; 13(8B):2673-2683. PubMed ID: 19220580
[TBL] [Abstract][Full Text] [Related]
18. Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Qun W; Tao Y
Hepatogastroenterology; 2010; 57(99-100):426-9. PubMed ID: 20698202
[TBL] [Abstract][Full Text] [Related]
19. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Huether A; Höpfner M; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2007 May; 73(9):1308-17. PubMed ID: 17266941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]